Using pharmacogenomics and therapeutic drug monitoring to guide drug selection and dosing in outpatient mental health comprehensive medication management
Mental Health Clinician · 01.07.2020 · 10 (4) · 254-258
DOI: 10.9740/mhc.2020.07.254 ↗Kurz gefasst
Fallbericht in der Zeitschrift Mental Health Clinician, online erschienen am 02.07.2020. Verfasst von Jacob T Brown und 2 weiteren Autor:innen. Beteiligte Einrichtung: Associate Professor, Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, Minnesota; Associate Professor…. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Pharmacogenomic (PGx) testing aided by therapeutic drug monitoring (TDM) has the potential to improve medication-related outcomes in some individuals prescribed psychiatric medications. Many commonly prescribed psychiatric medications are metabolized through polymorphic drug metabolizing enzymes such as cytochrome p450 (CYP) 2D6 (CYP2D6) and CYP2C19. Through PGx testing, clinicians can make biologically informed choices when selecting a new medication, and TDM may help inform dose adjustments or assess exposures to current treatments. Herein, we describe 2 complex case reports of individuals with multiple psychiatric diagnoses and extensive histories of medication failures who underwent PGx testing in addition to TDM as part of a pharmacist-led comprehensive medication therapy management evaluation in a community mental health clinic setting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Associate Professor, Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, Minnesota; Associate Professor, Medical School, Department of Psychiatry, University of Minnesota, M…
- Associate Professor, Department of Pharmaceutical Sciences and Pharmacy Practice, University of Minnesota College of Pharmacy, Duluth, Minnesota; Psychiatry Provider, Human Development Center, Duluth, Minnesota.
ORCID-Profile: Jacob T Brown, Jeffrey R Bishop, Mark E Schneiderhan
Zitieren
APA
Brown, J. T., Bishop, J. R., & Schneiderhan, M. E. (2020). Using pharmacogenomics and therapeutic drug monitoring to guide drug selection and dosing in outpatient mental health comprehensive medication management. Mental Health Clinician, 10(4), 254-258. https://doi.org/10.9740/mhc.2020.07.254
Vancouver
Brown JT, Bishop JR, Schneiderhan ME. Using pharmacogenomics and therapeutic drug monitoring to guide drug selection and dosing in outpatient mental health comprehensive medication management. Mental Health Clinician. 2020;10(4):254-258. doi:10.9740/mhc.2020.07.254
BibTeX
@article{Brown2020,
author = {Brown, Jacob T and Bishop, Jeffrey R and Schneiderhan, Mark E},
title = {Using pharmacogenomics and therapeutic drug monitoring to guide drug selection and dosing in outpatient mental health comprehensive medication management},
journal = {Mental Health Clinician},
year = {2020},
volume = {10},
number = {4},
pages = {254--258},
doi = {10.9740/mhc.2020.07.254}
}
EUVIMED